Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 6/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19260099 | 0.82 | P2RX7 (0.41) | CYP19A1UCHL1LPLLIPG | |
| SCHEMBL17501098 | 0.80 | UCHL1 (0.58) | UCHL1KMT2A | |
| SCHEMBL1604187 | 0.77 | POLB (0.36) | CYP19A1CYP11B2ESR2 | |
| SCHEMBL1530333 | 0.77 | LPL (0.39) | UCHL1KMT2ALPLLIPG | |
| SCHEMBL3261102 | 0.75 | FFAR1 (0.50) | CYP19A1CYP11B1CYP11B2ESR2LPL | |
| SCHEMBL1529947 | 0.71 | LPL (0.40) | UCHL1LPLLIPG | |
| SCHEMBL11651398 | 0.71 | KDM4E (0.62) | CYP19A1CYP11B1CYP11B2CYP2A6HTR2C | |
| SCHEMBL15375984 | 0.70 | FFAR1 (0.33) | UCHL1ESR2LPLLIPG | |
| SCHEMBL23423392 | 0.69 | CYP19A1 (0.54) | CYP19A1CYP11B1CYP11B2HTR2CCA12 | |
| SCHEMBL18113942 | 0.69 | GRM2 (0.34) | KMT2ALPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346353-A1 | CD73 INHIBITORS | ARCUS BIOSCIENCES, INC. | 2021-11-11 | — | — | US | disclosed |
| WO-2020046813-A1 | CD73 INHIBITORS | ARCUS BIOSCIENCES, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346353-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, NT5E | CYP19A1 2835/4885CYP11B1 3107/4885CYP11B2 3318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.